Latest news
Eli Lilly’s Jaypirca (pirtobrutinib) receives expanded indication from US FDA for certain patients with previously untreated CLL/SLL
The US Food and Drug Administration (FDA) has approved an additional indication for Eli Lilly and Company’s Jaypirca (pirtobrutinib, 100...
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases
CSL and Alentis Therapeutics have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has...
HanchorBio announces US FDA clearance of IND application for HCB303, a next-generation trispecific immunotherapy
The US Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for HCB303 developed by...
Lundbeck presents phase 1b data for Lu AF28996 in advanced Parkinson’s disease, as phase 2 trial begins
H Lundbeck has announced results from an open-label phase 1b trial evaluating Lu AF28996, a novel, investigational, oral prodrug...
Beactica Therapeutics selects BEA-28 as a preclinical candidate and first-in-class TEAD degrader for biomarker-selected cancers
Beactica Therapeutics AB, a Swedish precision medicine company, has selected BEA-28 as a preclinical candidate for its TEAD programme,...
Carbogen Amcis announces successful first FDA pre-approval inspection at its Vionnaz site
Carbogen Amcis, a leading pharmaceutical process development and active pharmaceutical ingredient (API) manufacturing company, announces the successful completion of the...
Thermo Fisher Scientific showcases new solutions and expanded capabilities to accelerate drug development at CPHI Milan 2026
Thermo Fisher Scientific, a world leader in serving science, is expanding its drug development, manufacturing and clinical capabilities to...
Novai publishes study supporting use of DARC imaging technology to identify patients at risk of central vision loss from macular atrophy
Novai, a medtech company combatting blindness and disability by pioneering early detection and intervention for eye and brain diseases,...
nPhase.AI becomes the industry’s first AI-native enterprise platform for end-to-end clinical data management
nPhase, a clinical research technology company, has launched nPhase.ai, the life sciences industry’s first enterprise platform for end-to-end clinical data...
Yourgene Health Insight DPYD assay achieves IVDR accreditation
Yourgene Health, an international molecular diagnostics company with a broad portfolio of integrated technologies and services, has announced the...
Takeda Receives US FDA approval of Mimrylo (rusfertide), marking a potential shift in the treatment paradigm for polycythaemia vera
Takeda has announced US FDA approval of the New Drug Application (NDA) for Mimrylo (rusfertide) for the treatment of...
uniQure announces submission of biologics license application for ifezuntirgene inilparvovec (AMT-130) in Huntington’s Disease
UniQure has applied for a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the accelerated approval...
- Advertisement -
- Advertisement -
- Advertisement -
- Advertisement -
Popular